193 related articles for article (PubMed ID: 38254859)
21. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Beck JT; Ismail A; Tolomeo C
Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
[TBL] [Abstract][Full Text] [Related]
22. lncRNA EZR‑AS1 knockdown represses proliferation, migration and invasion of cSCC via the PI3K/AKT signaling pathway.
Lu D; Sun L; Li Z; Mu Z
Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33236153
[TBL] [Abstract][Full Text] [Related]
23. Long noncoding RNA LINC00520 prevents the progression of cutaneous squamous cell carcinoma through the inactivation of the PI3K/Akt signaling pathway by downregulating EGFR.
Mei XL; Zhong S
Chin Med J (Engl); 2019 Feb; 132(4):454-465. PubMed ID: 30707166
[TBL] [Abstract][Full Text] [Related]
24. Anti-tumor effect of CDK inhibitors on CDKN2A-defective squamous cell lung cancer cells.
Jeong EH; Lee TG; Ko YJ; Kim SY; Kim HR; Kim H; Kim CH
Cell Oncol (Dordr); 2018 Dec; 41(6):663-675. PubMed ID: 30178167
[TBL] [Abstract][Full Text] [Related]
25. The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells.
Simioni C; Cani A; Martelli AM; Zauli G; Alameen AA; Ultimo S; Tabellini G; McCubrey JA; Capitani S; Neri LM
Oncotarget; 2015 Jul; 6(19):17147-60. PubMed ID: 26003166
[TBL] [Abstract][Full Text] [Related]
26. DW09849, a selective phosphatidylinositol 3-kinase (PI3K) inhibitor, prevents PI3K signaling and preferentially inhibits proliferation of cells containing the oncogenic mutation p110α (H1047R).
Liu JL; Gao GR; Zhang X; Cao SF; Guo CL; Wang X; Tong LJ; Ding J; Duan WH; Meng LH
J Pharmacol Exp Ther; 2014 Mar; 348(3):432-41. PubMed ID: 24361696
[TBL] [Abstract][Full Text] [Related]
27. Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9.
Saqub H; Proetsch-Gugerbauer H; Bezrookove V; Nosrati M; Vaquero EM; de Semir D; Ice RJ; McAllister S; Soroceanu L; Kashani-Sabet M; Osorio R; Dar AA
Sci Rep; 2020 Oct; 10(1):18489. PubMed ID: 33116269
[TBL] [Abstract][Full Text] [Related]
28. Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer.
Khan T; Seddon AM; Dalgleish AG; Khelwatty S; Ioannou N; Mudan S; Modjtahedi H
Oncol Rep; 2020 Dec; 44(6):2581-2594. PubMed ID: 33125153
[TBL] [Abstract][Full Text] [Related]
29. Dinaciclib, a Cyclin-Dependent Kinase Inhibitor Promotes Proteasomal Degradation of Mcl-1 and Enhances ABT-737-Mediated Cell Death in Malignant Human Glioma Cell Lines.
Jane EP; Premkumar DR; Cavaleri JM; Sutera PA; Rajasekar T; Pollack IF
J Pharmacol Exp Ther; 2016 Feb; 356(2):354-65. PubMed ID: 26585571
[TBL] [Abstract][Full Text] [Related]
30. A tEMTing target? Clinical and experimental evidence for epithelial-mesenchymal transition in the progression of cutaneous squamous cell carcinoma (a scoping systematic review).
Genenger B; Perry JR; Ashford B; Ranson M
Discov Oncol; 2022 Jun; 13(1):42. PubMed ID: 35666359
[TBL] [Abstract][Full Text] [Related]
31. A preferential p110alpha/gamma PI3K inhibitor attenuates experimental inflammation by suppressing the production of proinflammatory mediators in a NF-kappaB-dependent manner.
Dagia NM; Agarwal G; Kamath DV; Chetrapal-Kunwar A; Gupte RD; Jadhav MG; Dadarkar SS; Trivedi J; Kulkarni-Almeida AA; Kharas F; Fonseca LC; Kumar S; Bhonde MR
Am J Physiol Cell Physiol; 2010 Apr; 298(4):C929-41. PubMed ID: 20089935
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of the CDK inhibitor dinaciclib in vitro and in vivo in T-cell acute lymphoblastic leukemia.
Moharram SA; Shah K; Khanum F; Marhäll A; Gazi M; Kazi JU
Cancer Lett; 2017 Oct; 405():73-78. PubMed ID: 28756008
[TBL] [Abstract][Full Text] [Related]
33. Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription.
Thomas D; Powell JA; Vergez F; Segal DH; Nguyen NY; Baker A; Teh TC; Barry EF; Sarry JE; Lee EM; Nero TL; Jabbour AM; Pomilio G; Green BD; Manenti S; Glaser SP; Parker MW; Lopez AF; Ekert PG; Lock RB; Huang DC; Nilsson SK; Récher C; Wei AH; Guthridge MA
Blood; 2013 Aug; 122(5):738-48. PubMed ID: 23775716
[TBL] [Abstract][Full Text] [Related]
34. The Individual Effects of Cyclin-Dependent Kinase Inhibitors on Head and Neck Cancer Cells-A Systematic Analysis.
Schoenwaelder N; Salewski I; Engel N; Krause M; Schneider B; Müller M; Riess C; Lemcke H; Skorska A; Grosse-Thie C; Junghanss C; Maletzki C
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34063457
[TBL] [Abstract][Full Text] [Related]
35. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N
Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210
[TBL] [Abstract][Full Text] [Related]
36. PDK1 Mediates
Sambandam V; Frederick MJ; Shen L; Tong P; Rao X; Peng S; Singh R; Mazumdar T; Huang C; Li Q; Pickering CR; Myers JN; Wang J; Johnson FM
Clin Cancer Res; 2019 Jun; 25(11):3329-3340. PubMed ID: 30770351
[TBL] [Abstract][Full Text] [Related]
37. CD271 activation prevents low to high-risk progression of cutaneous squamous cell carcinoma and improves therapy outcomes.
Quadri M; Tiso N; Musmeci F; Morasso MI; Brooks SR; Bonetti LR; Panini R; Lotti R; Marconi A; Pincelli C; Palazzo E
J Exp Clin Cancer Res; 2023 Jul; 42(1):167. PubMed ID: 37443031
[TBL] [Abstract][Full Text] [Related]
38. Cutaneous Squamous Cell Carcinoma: A Review of High-Risk and Metastatic Disease.
Burton KA; Ashack KA; Khachemoune A
Am J Clin Dermatol; 2016 Oct; 17(5):491-508. PubMed ID: 27358187
[TBL] [Abstract][Full Text] [Related]
39. Dual blockade of lipid and cyclin-dependent kinases induces synthetic lethality in malignant glioma.
Cheng CK; Gustafson WC; Charron E; Houseman BT; Zunder E; Goga A; Gray NS; Pollok B; Oakes SA; James CD; Shokat KM; Weiss WA; Fan QW
Proc Natl Acad Sci U S A; 2012 Jul; 109(31):12722-7. PubMed ID: 22802621
[TBL] [Abstract][Full Text] [Related]
40. Downregulation of kynureninase restrains cutaneous squamous cell carcinoma proliferation and represses the PI3K/AKT pathway.
Ci C; Wu C; Lyu D; Chang X; He C; Liu W; Chen L; Ding W
Clin Exp Dermatol; 2020 Mar; 45(2):194-201. PubMed ID: 31419330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
